{"analyses":[{"ciLowerLimit":"0.14","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","estimateComment":"The hazard ratio was obtained from the unadjusted Cox Proportional Hazard Model. A hazard ratio \\< 1.0 indicates a longer average duration of response for talimogene laherparepvec relative to GM-CSF.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0868","pValueComment":"Descriptive","paramType":"Hazard Ratio (HR)","paramValue":"0.40","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events","groupId":"OG000","lowerLimit":"1.2","upperLimit":"NA","value":"2.8"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"description":"The duration of response is defined as the longest individual period from entering response (CR or PR as assessed by the EAC) to the first documented evidence of the patient no longer meeting the criteria for being in response or death, whichever is earlier. Responses were censored at the last assessment showing response.","dispersionType":"95% Confidence Interval","groups":[{"description":"GM-CSF was administered at a dose of 125 μg/m²/day subcutaneously for 14 days in 28-day cycles for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months.","id":"OG000","title":"GM-CSF"},{"description":"Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose was at a concentration of 10⁶ PFU/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months.","id":"OG001","title":"Talimogene Laherparepvec"}],"paramType":"MEDIAN","populationDescription":"Participants with an objective response (CR or PR) per EAC assessment.","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 21 December 2012; median follow-up time was 20 months.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}